Analysis of the incidence of uterine fibroid in Yekaterinburg

Background. Uterine fibroid (UF) is a benign tumor of the myometrium and is considered as one of the criteria for the state of women’s reproductive health. Objective information about the incidence of UF in a modern megalopolis allows us to assess the level of health of the female population, characterize the availability and quality of medical care, and plan its development.

Aim. To analyze the incidence and prevalence of UF according to the data of medical organizations in Yekaterinburg in 2016–2022.

Materials and methods. An epidemiological study of the incidence and prevalence of the adult female population of the city of Yekaterinburg in 2016–2022 was conducted. For the analysis, we used Form No. 12 of the Federal Statistical Observation of Medical Organizations located in the city. The incidence rates were calculated for the average annual female population aged 18 years and over, expressed in ⁰/₀₀₀₀. Absolute growth (decrease), growth rate (decrease), growth rate (decrease), average growth rate (decrease) were studied. The long-term dynamics of the indicators was determined using the average growth rate.

Results. The incidence of UF was 130.89⁰/₀₀₀₀, and the prevalence was 735.80⁰/₀₀₀₀ in 2016. During the pre-pandemic period, the indicators increased significantly in 2019 compared to the baseline year 2016 (р < 0.001). The incidence increased by 1.96 times, the prevalence – by 1.39 times. The indicators decreased to the level of 2016 during the pandemic of new coronavirus infection (2020–2022) (р >0.05).

Conclusion. The obtained dynamics of incidence and prevalence of UF in the population of women in a modern megalopolis is considered as a criterion for the state of women’s health, accessibility and quality of preventive and planned medical care for gynecological patients. The results of the study are recommended for planning medical care for women and can form the basis for continuing epidemiological studies.

1. Uterine fibroids. Clinical recommendations. Moscow, 2022. 35 p. Available at: https://roag-portal.ru/recommendations_gynecology. (In Russ.).

2. International Classification of Diseases 10th revision (ICD-10). Available at: https://mkb-10.com/. (In Russ.).

3. Machado-Lopez A., Simón C., Mas A. Molecular and cellular insights into the development of uterine fibroids. Int J Mol Sci 2021;22(16):8483. DOI: 10.3390/ijms22168483

4. Langton C.R., Gerety M., Harmon Q.E. et al. Keloids, hypertrophic scars, and uterine fibroid development: A prospective ultrasound study of black and African American women. F S Sci 2023;4(2):172–80. DOI: 10.1016/j.xfss.2023.03.006

5. Roberts M.E., Aynardi J.T., Chu C.S. Uterine leiomyosarcoma: A review of the literature and update on management options. Gynecol Oncol 2018;151(3):562–72. DOI: 10.1016/j.ygyno.2018.09.010

6. Ricci G., Scrimin F., Sartore A et al. Characteristics of submucous myomas and the risk of anemia. Medicina (Kaunas) 2022;58(11):1652. DOI: 10.3390/medicina58111652

7. Navarro A., Bariani M.V., Yang Q., Al-Hendy A. Understanding the impact of uterine fibroids on human endometrium function. Front Cell Dev Biol 2021;9:633180. DOI: 10.3389/fcell.2021.633180

8. Pérez-Roncero G.R., López-Baena M.T., Ornat L. et al. Uterine fibroids and preterm birth risk: A systematic review and metaanalysis. J Obstet Gynaecol Res 2020;46(9):1711–27. DOI: 10.1111/jog.14343

9. Yu O., Scholes D., Schulze-Rath R. et al. A US population-based study of uterine fibroid diagnosis incidence, trends, and prevalence: 2005 through 2014. Am J Obstet Gynecol 2018;219(6):591.e1–8. DOI: 10.1016/j.ajog.2018.09.039

10. Sadykhova E.E., Bezhenar V.F., Arakelyan B.V. et al. Opportunities for the use of X-ray endosurgical hemostasis in complex treatment of uterine myoma in patients with severe anemia. Uralskiy meditsinskiy zhurnal = Ural Medical Journal 2019;3(171):59–63. (In Russ.). DOI: 10.25694/URMJ.2019.03.23

11. Podzolkova N.M., Korennaya V.V., Koloda Yu.A. et al. Functional outcomes of myomectomy. Problemy reproduktsii = Russian Journal of Human Reproduction 2020;26(3):31–8. (In Russ.). DOI: 10.17116/repro20202603131

12. Marsh E.E., Al-Hendy A., Kappus D. et al. Prevalence, and treatment of uterine fibroids: A survey of U.S. women. J Womens Health (Larchmt) 2018;27(11):1359–67. DOI: 10.1089/jwh.2018.7076

13. Hartmann K.E., Fonnesbeck C., Surawicz T. et al. Management of uterine fibroids. AHRQ comparative efectiveness review. Rockville, 2017. Available at: https://efectivehealthcare.ahrq.gov/sites/default/fles/pdf/cer-195-uterine-fbroids-fnal-revision.pdf.

14. Cheng L.C., Li H.Y., Gong Q.Q. et al. Global, regional, and national burden of uterine fibroids in the last 30 years: Estimates from the 1990 to 2019 Global Burden of Disease Study. Front Med (Lausanne) 2022;9:1003605. DOI: 10.3389/fmed.2022.1003605

15. Harris H.R., Petrick J.L., Rosenberg L. The epidemiology of uterine fibroids: Where do we go from here? Fertil Steril 2022;117(4):841, 842. DOI: 10.1016/j.fertnstert.2022.01.037

16. Wise L.A., Laughlin-Tommaso S.K. Epidemiology of uterine fibroids: From menarche to menopause. Clin Obstet Gynecol 2016;59(1):2–24. DOI: 10.1097/GRF.0000000000000164

17. Sung H., Siegel R.L., Torre L.A. et al. Global patterns in excess body weight and the associated cancer burden. CA Cancer J Clin 2019;69(2):88–112. DOI: 10.3322/caac.21499

18. Takala H., Yang Q., El Razek A.M.A. et al. Alcohol consumption and risk of uterine fibroids. Curr Mol Med 2020;20(4):247–58. DOI: 10.2174/1566524019666191014170912

19. Morhason-Bello I.O., Adebamowo C.A. Epidemiology of uterine fibroid in black African women: A systematic scoping review. BMJ Open 2022;12:e052053. DOI: 10.1136/bmjopen-2021-052053

20. Carey C.M., Katon J., Bossick A. et al. Uterine weight as a modifier of black/white racial disparities in minimally invasive hysterectomy among veterans with fibroids in the Veterans Health Administration. Health Equity 2022;6(1):909–16. Available at: https://www.liebertpub.com/doi/abs/10.1089/heq.2022.0130.

21. Ngorili G.S., Yadav B.B., Takalkar A.A. Epidemiological study of uterine fibroids: Our experience from urban Maharashtra. Int J Reprod Contracept Obstet Gynecol 2022;11:2101–5. DOI: 10.18203/2320-1770.ijrcog20221918

22. Leyland N., Leonardi M., Murji A. et al. A call-to-action for clinicians to implement evidence-based best practices when caring for women with uterine fibroids. Reprod Sci 2022;29:1188–96. DOI: 10.1007/s43032-022-00877-3

23. Leonov S.A., Son I.M., Savina A.A. Guidelines for the analysis of the main statistical indicators of the health status of the population and the activities of medical organizations. Moscow, 2015. 53 p. (In Russ.).

24. Federal State Statistics Service. Order No. 409 dated November 22, 2010 “On the approval of the Practical Manual on Health Statistics”. Moscow, 2010. 102 p. (In Russ.).

25. Kucherenko V.Z., Avksentieva M.V., Alekseeva V.M. et al. Application of statistical analysis methods for the study of public health and healthcare: A textbook. Moscow: GEOTAR-Media, 2011. 256 p. (In Russ.).

26. Slobodenyuk A.V., Kosova A.A., An R.N. Epidemiological analysis: A textbook. Yekaterinburg, 2015. 36 p. (In Russ.).

27. Rebrova O.Yu. Statistical analysis of medical data. Application of the STATISTICA application software package. Мoscow: MediaSfera, 2006. 305 р. (In Russ.).